Where Science Meets Real-World Applications
ATTD-ASIA is a groundbreaking expansion of ATTD – the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes assemble with the aim of sharing knowledge and developing collaborations.
We’re working to provide a Scientific Program filled with the latest therapies for diabetes management!
You are invited to explore the initial Scientific Program structure
* Subject to changes. Correct as of 1 June 2026
Initial Titles & Speakers
Using CGM to understand preeclampsia
Naoko Arata, Japan
How Do We Use CGM Data in Practice to Improve Care?
Richard Bergenstal, USA
Prevalence of other types of diabetes in Asia
Julian Chan, Hong Kong
CGM-detected nocturnal hypoglycemia and sleep
Suresh Rama Chandran, Singapore
CGM Metrics in People Without Diabetes in Asia: Differentiating Prediabetes From Normoglycemia
Suresh Rama Chandran, Singapore
CGM guided unusual interventions in T2DM
Manoj Chawla, India
AI and hypoglycemia prediction
Pratik Choudhary, UK
CGM and AID in Chronic Kidney Disease
Elaine Chow, Hong Kong
Frontiers in Type 1 Diabetes Care: From Presymptomatic Stages to Transplantation
Precision Diagnostics and Therapeutics in Young-Onset Diabetes in Asia
Ronald CW Ma, Singapore
Harnessing the Power of Data to Drive New Models of Care in Paediatric Diabetes
Liz Davis, Australia
Most Youth with Diabetes Using Advanced Hybrid Closed-Loop Therapy Don’t Attain Glycaemic Targets: What More Can We Do?
Martin de Bock, New Zealand
Responsible AI Use in Diabetes Care
Amit Dey, India
Using GLP-1 analogues to prevent gestational diabetes
Judie Dodd, Australia
TITR with AID during and after Exercise
Klemen Dovc, Slovenia
Diabetes in Asia: Implications for Subtyping and CGM Accuracy
Daphne Gardner, Singapore
Consensus on Incretin Use in Type 1 Diabetes
Satish Garg, USA
Regional perspectives regarding diabetes technology
Amit Gupta, India
Youth-Onset Type 2 Diabetes in Asia: Bridging Guidelines and Real-World Practice
Muhammad Yazid Jalaludin, Malaysia
Evaluation Of CGM-Based Insulin Dose Guidance System In People With Type 1 And Type 2 Diabetes
Andrej Janež, Slovenia
CGM-derived glucose excursion patterns and their impact on GMI–HbA1c discordance in individuals with T1D
Sang-Man Jin, Republic of Korea
The role of EMRs in India
Jothydev Kesavadev, India
CGM and smart pens in people living with type 2 diabetes using insulin
Jae Hyeon Kim, Republic of Korea
Using longitudinal data collection to improve outcomes for people with different stages of type 1 diabetes in Japan
Noriko Kodani, Japan
Frailty Changes The Diabetes Playbook: Lifestyle Medicine That Protects Function
Eng Sing Lee, Singapore
CGM metrics for predicting GDM in Asia
Queenie Ling Jun Li, Singapore
The use of diabetes tech in the elderly
Julia Mader, Austria
CGM Adoption in India and Challenges
Anuj Maheshwari, India
Defining the “Full Closed Loop” by outcome targets
Brynn Marks, USA
Monogenic diabetes and its prevalence in Asia
Viswanathan Mohan, India
Continuous Glucose Monitoring in Gestational Diabetes
Sun-Joon Moon, Republic of Korea
AI in Diabetes Care: Tool, Teammate, or Decision-Maker?
Revital Nimri,Israel
A Practical Meal Correction Algorithm for User-Friendly Diabetes Clinical Decision Support System
Rimei Nishimura, Japan
New pharmacological treatment in children with type 2 diabetes
Rimei Nishimura, Japan
Integrating CGM and automation of insulin delivery into hospital care
David O’Neal, AustraliaNovel avenues for potential future therapies aimed at improving metabolic control in diabetes
David O’Neal, Australia
Lifestyle Medicine: The Six Pillars—Do We Practice What We Preach?
Emina Obarcanin, Singapore
Prerequisites for accelerating clinical adoption of cell therapy in T1D
Jon Odorico, USA
From Prediction to Prevention: AI-Driven Early Detection of Type 1 Diabetes
Tal Oron, Israel
Cell-based therapies in T1D
Lorenzo Piemonti,Italy
Transforming Diabetes Care With Lifestyle Medicine
Siva Poobalasingam, Malaysia
Medical Insights From CGM Beyond Glucose Control
Sarah Price, Australia
CGM in T2D: From Early Intervention to Management
Banshi Saboo, India
Evidence of using AID in T2D and how AID could reduce therapeutic inertia
Viral Shah, USA
Barriers to CGM Use as a Behavioral Tool
Amit Shapira, USA
Sex Differences in Continuous Glucose Monitoring Profiles: Insights From a Non-Diabetic Population
Smadar Shilo, Israel
What Can a CGM Signal Tell Us About
Insulin Resistance in Non-Diabetic
Adults?
Smadar Shilo, Israel
Optimizing Diabetes Care in Older Adults in Japan
Ryo Suzuki, Japan
Using GLP-1 RA with exercise in T1D
Stephen Twigg, Australia
Opening Lecture: Toward the development of personalized diabetes care
Kohjiro Ueki, Japan
How can we screen children for type 2 diabetes?
Tatsuhiko Urakami, Japan
From Incretin-Based Therapies to iPSC-Based Regenerative Medicine: New Frontiers in Diabetes Care
Daisuke Yabe, Japan
Clinical Implications of TITR, CV, and GRI
Jee Hee Yoo, Republic of Korea
Clinical Utility and Interpretation of CGM in Prediabetes
Jee Hee Yoo, Republic of Korea
National big data-based insights into pediatric diabetes epidemiology and complications
Jae Hyun Kim, Republic of Korea